Bridgeway Capital Management’s Caribou Biosciences CRBU Stock Holding History

Bridgeway Capital Management’s Portfolio CRBU Stock Details CRBU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$232K	Hold	132,000	–	–	﹤0.01%	1026
2026 Q1	$251K	Sell	132,000 -16,500	-11%	-$28.3K	0.01%	979
2025 Q4	$236K	Hold	148,500	–	–	﹤0.01%	988
2025 Q3	$346K	Hold	148,500	–	–	0.01%	886
2025 Q2	$187K	Buy	148,500 +40,000	+37%	+$39.3K	﹤0.01%	975
2025 Q1	$99.1K	Sell	108,500 -97,400	-47%	-$127K	﹤0.01%	1037
2024 Q4	$327K	Sell	205,900 -28,501	-12%	-$57.3K	0.01%	903
2024 Q3	$459K	Buy	+234,401	New	+$480K	0.01%	882

Other funds holding CRBU

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Bridgeway Capital Management's CRBU Position: Q2 2026 in Review

Bridgeway Capital Management held its Caribou Biosciences (CRBU) position steady in Q2 2026 at 132,000 shares worth $232K. The position accounts for ﹤0.01% of the portfolio, ranked #1026.

Bridgeway Capital Management first reported a position in CRBU in Q3 2024 and has held it in 8 quarters since. The position peaked at $459K in Q3 2024. 137 funds tracked by Wall St. Rank hold CRBU as of Q2 2026.

Bridgeway Capital Management held 132,000 shares of Caribou Biosciences worth $232K as of Q2 2026.
Bridgeway Capital Management left its Caribou Biosciences share count unchanged in Q2 2026.
Caribou Biosciences made up ﹤0.01% of Bridgeway Capital Management's portfolio in Q2 2026, its #1026 holding.
Bridgeway Capital Management first reported a position in Caribou Biosciences in Q3 2024 and has held it in 8 quarters since.
Bridgeway Capital Management's Caribou Biosciences position peaked at $459K in Q3 2024.
137 funds tracked by Wall St. Rank held Caribou Biosciences as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.